TN2014000470A1 - Bicyclically substituted uracils and the use thereof - Google Patents

Bicyclically substituted uracils and the use thereof

Info

Publication number: TN2014000470A1
Authority: TN; Tunisia
Prior art keywords: substituted uracils; bicyclically substituted; prophylaxis; diseases; treatment
Prior art date: 2012-05-09

Application number

TN2014000470A

Other languages

English (en)

Inventor

Chantal Fürstner

Jens Ackerstaff

Alexander Straub

Heinrich Meier

Hanna Tinel

Katja Zimmermann

Adrian Tersteegen

Dmitry Zubov

Raimund Kast

Jens Schamberger

Martina Schäfer

Kirsten Börngen

Original Assignee

Bayer Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-09

Filing date

2014-11-07

Publication date

2016-03-30

2014-11-07 Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG

2016-03-30 Publication of TN2014000470A1 publication Critical patent/TN2014000470A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

TN2014000470A 2012-05-09 2014-11-07 Bicyclically substituted uracils and the use thereof TN2014000470A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP12167231		2012-05-09
PCT/EP2013/059286 WO2013167495A1 (fr)	2012-05-09	2013-05-03	Uraciles à substitution bicyclique et leur utilisation

Publications (1)

Publication Number	Publication Date
TN2014000470A1 true TN2014000470A1 (en)	2016-03-30

Family

ID=48289199

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2014000470A TN2014000470A1 (en)	2012-05-09	2014-11-07	Bicyclically substituted uracils and the use thereof

Country Status (44)

Country	Link
US (5)	US9481672B2 (fr)
EP (2)	EP2847190B1 (fr)
JP (2)	JP6141414B2 (fr)
KR (1)	KR102083281B1 (fr)
CN (2)	CN106983751B (fr)
AP (1)	AP2014008096A0 (fr)
AR (1)	AR090994A1 (fr)
AU (2)	AU2013258223B2 (fr)
BR (1)	BR112014028086B1 (fr)
CA (1)	CA2872906C (fr)
CL (1)	CL2014003031A1 (fr)
CO (1)	CO7131375A2 (fr)
CR (1)	CR20140513A (fr)
CU (1)	CU20140129A7 (fr)
CY (2)	CY1118900T1 (fr)
DK (2)	DK3045456T3 (fr)
DO (1)	DOP2014000255A (fr)
EA (2)	EA030383B9 (fr)
EC (1)	ECSP14026138A (fr)
ES (2)	ES2581537T3 (fr)
HK (1)	HK1202873A1 (fr)
HR (2)	HRP20160796T1 (fr)
HU (2)	HUE035462T2 (fr)
IL (2)	IL235438A (fr)
JO (1)	JO3290B1 (fr)
LT (1)	LT3045456T (fr)
MX (2)	MX367599B (fr)
MY (1)	MY181828A (fr)
NO (1)	NO3045456T3 (fr)
NZ (1)	NZ701700A (fr)
PE (1)	PE20142301A1 (fr)
PH (1)	PH12014502496B1 (fr)
PL (2)	PL3045456T3 (fr)
PT (2)	PT3045456T (fr)
RS (2)	RS54901B1 (fr)
SA (1)	SA113340533B1 (fr)
SG (1)	SG10202003175QA (fr)
SI (2)	SI2847190T1 (fr)
TN (1)	TN2014000470A1 (fr)
TW (2)	TWI635085B (fr)
UA (1)	UA112897C2 (fr)
UY (1)	UY34797A (fr)
WO (1)	WO2013167495A1 (fr)
ZA (1)	ZA201408146B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA112897C2 (uk) *	2012-05-09	2016-11-10	Байєр Фарма Акцієнгезелльшафт	Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
CA2929753A1 (fr) *	2013-11-08	2015-05-14	Bayer Pharma Aktiengesellschaft	Uraciles substitues et leur utilisation
EP3066095A1 (fr) *	2013-11-08	2016-09-14	Bayer Pharma Aktiengesellschaft	1,2,4-triazine-3,5-diones substitués et leur utilisation comme inhibiteurs de la chimase
WO2015067651A1 (fr) *	2013-11-08	2015-05-14	Bayer Pharma Aktiengesellschaft	Uraciles substitués comme inhibiteurs de la chimase
CA2929780C (fr) *	2013-11-08	2022-03-22	Bayer Pharma Aktiengesellschaft	Sels de l'acide 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)-4-(trifluoromethyl)-2,3-dihydro-lh-inden-1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylique
WO2017162661A1 (fr)	2016-03-22	2017-09-28	Bayer Pharma Aktiengesellschaft	1h-benzo[de]isoquinoléine-1,3(2h)-diones
EP3338780A1 (fr) *	2016-12-20	2018-06-27	Bayer Pharma Aktiengesellschaft	Utilisation d'inhibiteurs de chymase pour le traitement de l'endométriose, fibrose post opératoire et maladies caractérisées par la formation de fibrose
WO2018197333A1 (fr)	2017-04-27	2018-11-01	Bayer Aktiengesellschaft	Antagonistes sélectifs du récepteur adrénergique alpha2c, seuls ou en association avec des inhibiteurs de chymase destinés à être utilisés dans le traitement et/ou la prophylaxie de maladies artérielles périphériques (pad)
JOP20200287A1 (ar)	2018-05-15	2020-11-09	Bayer Ag	بنزاميدات مستبدلة بـ 3،1- ثيازول-2- يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية
CN110229067A (zh) *	2019-06-05	2019-09-13	南京焕然生物科技有限公司	一种2-氨基茚制备方法
WO2021000933A1 (fr) *	2019-07-03	2021-01-07	南京明德新药研发有限公司	Composés de pyrimidinone utilisés en tant qu'inhibiteurs de chymase et leur utilisation
US11618751B1 (en)	2022-03-25	2023-04-04	Ventus Therapeutics U.S., Inc.	Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CN111440141A (zh) *	2020-05-20	2020-07-24	安徽泽升科技有限公司	一种羟甲基取代芳杂环类化合物的制备方法
WO2022135534A1 (fr) *	2020-12-25	2022-06-30	广东东阳光药业有限公司	Composé bicyclique azoté substitué et son utilisation
CN114685472B (zh) *	2020-12-25	2024-04-26	广东东阳光药业股份有限公司	多取代的尿嘧啶衍生物及其用途
CN114671856B (zh) *	2020-12-25	2023-10-20	广东东阳光药业股份有限公司	多取代的尿嘧啶衍生物及其用途
EP4444728A1 (fr) *	2021-12-06	2024-10-16	Pretzel Therapeutics, Inc.	Composés inhibiteurs de lonp1, utilisations et méthodes
AU2023251136A1 (en) *	2022-04-05	2024-10-17	Bayer Aktiengesellschaft	Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6403599B1 (en) *	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
US6114532A (en)	1998-02-03	2000-09-05	Boehringer Ingelheim Pharma Kg	Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
DE19834044A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Neue substituierte Pyrazolderivate
DE19834047A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Substituierte Pyrazolderivate
US6458952B1 (en)	1999-05-19	2002-10-01	Pharmacia Corporation	Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
EP1219611A4 (fr)	1999-09-03	2003-03-19	Ajinomoto Kk	Nouveaux procedes de preparation de derives d'oxazepine
DE19943635A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de)	1999-09-13	2001-04-12	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
GB0021315D0 (en) *	2000-08-30	2000-10-18	Dainippon Pharmaceutical Co	Heterocyclic compounds and intermediates thereof
AR031176A1 (es)	2000-11-22	2003-09-10	Bayer Ag	Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
JP2003017508A (ja)	2001-07-05	2003-01-17	Nec Corp	電界効果トランジスタ
AR038536A1 (es)	2002-02-25	2005-01-19	Upjohn Co	N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
DE10220570A1 (de)	2002-05-08	2003-11-20	Bayer Ag	Carbamat-substituierte Pyrazolopyridine
JP2003342265A (ja) *	2002-05-22	2003-12-03	Senju Pharmaceut Co Ltd	トリアゾリジン誘導体およびその医薬用途
US20060079554A1 (en)	2002-12-06	2006-04-13	Barry Peter C	Inhibitors of monomine uptake
EP1666067A4 (fr) *	2003-08-22	2009-07-22	Teijin Pharma Ltd	Medicament contenant un inhibiteur de chymase en tant qu'agent actif
DE102004004928A1 (de)	2004-01-31	2005-08-18	Bayer Healthcare Ag	Dibenzoxazepine II
EP1735319B1 (fr)	2004-03-26	2017-05-03	MethylGene Inc.	Inhibiteurs d'histone desacetylase
US7507748B2 (en)	2004-07-22	2009-03-24	Amgen Inc.	Substituted aryl-amine derivatives and methods of use
WO2006071940A2 (fr)	2004-12-23	2006-07-06	Deciphera Pharmaceuticals, Llc	Modulateurs d'enzymes et traitements
WO2006119504A2 (fr)	2005-05-04	2006-11-09	Renovis, Inc.	Composes heterocycliques fusionnes, leurs compositions et leurs utilisations
WO2007007161A2 (fr) *	2005-07-08	2007-01-18	Orchid Research Laboratories Limited	Nouveaux derives bioactifs
EP1968950A4 (fr)	2005-12-19	2010-04-28	Genentech Inc	Inhibiteurs de pyrimidine kinase
ATE443061T1 (de)	2006-02-14	2009-10-15	Pfizer Prod Inc	Benzoxazinon- und benzoxazepinonoxazolidinone als antibakterielle mittel
JO2934B1 (en) *	2006-06-23	2015-09-15	سميث كلاين بيتشام كوربوريشن	Prolyl hydroxylase inhibitors
US7790756B2 (en)	2006-10-11	2010-09-07	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
GB0622472D0 (en)	2006-11-10	2006-12-20	Addex Pharmaceuticals Sa	Novel heterocyclic derivatives
US8314087B2 (en)	2007-02-16	2012-11-20	Amgen Inc.	Nitrogen-containing heterocyclyl ketones and methods of use
MX2009011059A (es)	2007-04-13	2009-11-26	Vertex Pharma	Aminopirimidinas utiles como inhibidores de cinasas.
WO2009049112A1 (fr)	2007-10-10	2009-04-16	Smithkline Beecham Corporation	Inhibiteurs de la prolyl hydroxylase
CA2702524A1 (fr)	2007-10-19	2009-04-23	Boehringer Ingelheim International Gmbh	Piperazino-dihydrothienopyrimidines substituees par un heterocycle
MY152042A (en) *	2008-05-05	2014-08-15	Actelion Pharmaceuticals Ltd	3,4- substituted piperidine derivatives as renin inhibitors
DE102008030091B4 (de)	2008-06-25	2011-03-03	Resprotect Gmbh	Uracilderivate und deren Verwendung
BRPI0913368A2 (pt)	2008-06-25	2015-11-24	Daiichi Sankyo Co Ltd	compostos de ácido carboxílico
UA112897C2 (uk) *	2012-05-09	2016-11-10	Байєр Фарма Акцієнгезелльшафт	Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань

2013
- 2013-03-05 UA UAA201413167A patent/UA112897C2/uk unknown
- 2013-05-03 DK DK16154186.7T patent/DK3045456T3/da active
- 2013-05-03 PT PT161541867T patent/PT3045456T/pt unknown
- 2013-05-03 LT LTEP16154186.7T patent/LT3045456T/lt unknown
- 2013-05-03 EA EA201492040A patent/EA030383B9/ru not_active IP Right Cessation
- 2013-05-03 AU AU2013258223A patent/AU2013258223B2/en active Active
- 2013-05-03 EA EA201790032A patent/EA031222B1/ru not_active IP Right Cessation
- 2013-05-03 NO NO16154186A patent/NO3045456T3/no unknown
- 2013-05-03 ES ES13720407.9T patent/ES2581537T3/es active Active
- 2013-05-03 RS RS20160510A patent/RS54901B1/sr unknown
- 2013-05-03 BR BR112014028086-0A patent/BR112014028086B1/pt active IP Right Grant
- 2013-05-03 SI SI201330233A patent/SI2847190T1/sl unknown
- 2013-05-03 AP AP2014008096A patent/AP2014008096A0/xx unknown
- 2013-05-03 EP EP13720407.9A patent/EP2847190B1/fr active Active
- 2013-05-03 PE PE2014001986A patent/PE20142301A1/es active IP Right Grant
- 2013-05-03 ES ES16154186.7T patent/ES2657315T3/es active Active
- 2013-05-03 RS RS20180076A patent/RS56784B1/sr unknown
- 2013-05-03 HU HUE16154186A patent/HUE035462T2/en unknown
- 2013-05-03 EP EP16154186.7A patent/EP3045456B1/fr active Active
- 2013-05-03 PT PT137204079T patent/PT2847190T/pt unknown
- 2013-05-03 DK DK13720407.9T patent/DK2847190T3/en active
- 2013-05-03 MY MYPI2014703273A patent/MY181828A/en unknown
- 2013-05-03 KR KR1020147034155A patent/KR102083281B1/ko active IP Right Grant
- 2013-05-03 MX MX2018008811A patent/MX367599B/es unknown
- 2013-05-03 SI SI201330934T patent/SI3045456T1/en unknown
- 2013-05-03 JP JP2015510754A patent/JP6141414B2/ja active Active
- 2013-05-03 PL PL16154186T patent/PL3045456T3/pl unknown
- 2013-05-03 MX MX2014013571A patent/MX357712B/es active IP Right Grant
- 2013-05-03 WO PCT/EP2013/059286 patent/WO2013167495A1/fr active Application Filing
- 2013-05-03 CA CA2872906A patent/CA2872906C/fr active Active
- 2013-05-03 US US14/399,945 patent/US9481672B2/en active Active
- 2013-05-03 CN CN201710219097.9A patent/CN106983751B/zh active Active
- 2013-05-03 NZ NZ701700A patent/NZ701700A/en unknown
- 2013-05-03 SG SG10202003175QA patent/SG10202003175QA/en unknown
- 2013-05-03 CN CN201380034776.9A patent/CN104395310B/zh active Active
- 2013-05-03 PL PL13720407.9T patent/PL2847190T3/pl unknown
- 2013-05-03 HU HUE13720407A patent/HUE029366T2/en unknown
- 2013-05-08 AR ARP130101600A patent/AR090994A1/es active IP Right Grant
- 2013-05-08 TW TW106105676A patent/TWI635085B/zh active
- 2013-05-08 TW TW102116308A patent/TWI579278B/zh active
- 2013-05-08 UY UY0001034797A patent/UY34797A/es active IP Right Grant
- 2013-05-08 SA SA113340533A patent/SA113340533B1/ar unknown
- 2013-05-08 JO JOP/2013/0144A patent/JO3290B1/ar active
2014
- 2014-11-02 IL IL235438A patent/IL235438A/en active IP Right Grant
- 2014-11-06 CU CU2014000129A patent/CU20140129A7/es unknown
- 2014-11-07 PH PH12014502496A patent/PH12014502496B1/en unknown
- 2014-11-07 CR CR20140513A patent/CR20140513A/es unknown
- 2014-11-07 CL CL2014003031A patent/CL2014003031A1/es unknown
- 2014-11-07 CO CO14246970A patent/CO7131375A2/es unknown
- 2014-11-07 ZA ZA2014/08146A patent/ZA201408146B/en unknown
- 2014-11-07 DO DO2014000255A patent/DOP2014000255A/es unknown
- 2014-11-07 EC ECIEPI201426138A patent/ECSP14026138A/es unknown
- 2014-11-07 TN TN2014000470A patent/TN2014000470A1/fr unknown
2015
- 2015-04-09 HK HK15103474.2A patent/HK1202873A1/xx unknown
2016
- 2016-07-06 CY CY20161100636T patent/CY1118900T1/el unknown
- 2016-07-06 HR HRP20160796TT patent/HRP20160796T1/hr unknown
- 2016-10-07 US US15/288,982 patent/US9949978B2/en active Active
- 2016-10-07 US US15/288,968 patent/US9949977B2/en active Active
2017
- 2017-05-02 JP JP2017091842A patent/JP6367421B2/ja active Active
- 2017-08-10 IL IL253950A patent/IL253950B/en active IP Right Grant
- 2017-11-22 AU AU2017265047A patent/AU2017265047B2/en active Active
2018
- 2018-01-23 HR HRP20180125TT patent/HRP20180125T1/hr unknown
- 2018-01-24 CY CY20181100095T patent/CY1119840T1/el unknown
- 2018-03-05 US US15/912,185 patent/US10300062B2/en active Active
2019
- 2019-04-02 US US16/373,487 patent/US20200061063A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL253950B (en)	2019-07-31
EP3045456A1 (fr)	2016-07-20
CR20140513A (es)	2014-12-02
TW201406744A (zh)	2014-02-16
AR090994A1 (es)	2014-12-30
AU2013258223A1 (en)	2014-11-27
EA201790032A1 (ru)	2017-05-31
BR112014028086A2 (pt)	2020-12-01
CA2872906A1 (fr)	2013-11-14
EA031222B1 (ru)	2018-12-28
DOP2014000255A (es)	2015-02-27
CY1118900T1 (el)	2018-01-10
CN104395310A (zh)	2015-03-04
HK1202873A1 (en)	2015-10-09
HRP20160796T1 (hr)	2016-08-12
DK3045456T3 (da)	2018-01-29
AP2014008096A0 (en)	2014-12-31
AU2017265047A1 (en)	2017-12-14
SI2847190T1 (sl)	2016-08-31
MX2014013571A (es)	2014-12-08
AU2017265047B2 (en)	2019-04-18
CU20140129A7 (es)	2015-02-26
ZA201408146B (en)	2017-01-25
PH12014502496A1 (en)	2015-01-12
EP2847190B1 (fr)	2016-04-06
HUE035462T2 (en)	2018-05-02
CY1119840T1 (el)	2018-06-27
JP2015516000A (ja)	2015-06-04
CL2014003031A1 (es)	2015-03-06
US20150148340A1 (en)	2015-05-28
US20180256576A1 (en)	2018-09-13
MY181828A (en)	2021-01-08
US9481672B2 (en)	2016-11-01
CN106983751B (zh)	2020-01-07
RS56784B1 (sr)	2018-04-30
TW201734007A (zh)	2017-10-01
JP6141414B2 (ja)	2017-06-07
SA113340533B1 (ar)	2015-10-12
JP2017160242A (ja)	2017-09-14
US20200061063A1 (en)	2020-02-27
SI3045456T1 (en)	2018-03-30
WO2013167495A1 (fr)	2013-11-14
US9949977B2 (en)	2018-04-24
IL253950A0 (en)	2017-10-31
CN104395310B (zh)	2017-05-03
TWI635085B (zh)	2018-09-11
CO7131375A2 (es)	2014-12-01
PL2847190T3 (pl)	2016-12-30
UA112897C2 (uk)	2016-11-10
EP3045456B1 (fr)	2017-10-25
EA201492040A1 (ru)	2015-12-30
KR102083281B1 (ko)	2020-05-29
PE20142301A1 (es)	2014-12-19
IL235438A (en)	2017-08-31
KR20150016548A (ko)	2015-02-12
JP6367421B2 (ja)	2018-08-01
TWI579278B (zh)	2017-04-21
CN106983751A (zh)	2017-07-28
ES2657315T3 (es)	2018-03-02
SG10202003175QA (en)	2020-05-28
PT3045456T (pt)	2018-01-30
ES2581537T3 (es)	2016-09-06
RS54901B1 (sr)	2016-10-31
US20170020875A1 (en)	2017-01-26
EP2847190A1 (fr)	2015-03-18
JO3290B1 (ar)	2018-09-16
UY34797A (es)	2013-11-29
BR112014028086B1 (pt)	2021-09-21
CA2872906C (fr)	2020-08-04
DK2847190T3 (en)	2016-07-25
HRP20180125T1 (hr)	2018-02-23
NZ701700A (en)	2016-09-30
NO3045456T3 (fr)	2018-03-24
US10300062B2 (en)	2019-05-28
EA030383B9 (ru)	2018-12-28
US20170020876A1 (en)	2017-01-26
LT3045456T (lt)	2018-02-12
HUE029366T2 (en)	2017-02-28
AU2013258223B2 (en)	2017-11-09
MX357712B (es)	2018-07-20
MX367599B (es)	2019-08-28
US9949978B2 (en)	2018-04-24
PL3045456T3 (pl)	2018-03-30
PH12014502496B1 (en)	2015-01-12
EA030383B1 (ru)	2018-07-31
ECSP14026138A (es)	2015-12-31
PT2847190T (pt)	2016-07-14

Publication	Publication Date	Title
TN2014000470A1 (en)	2016-03-30	Bicyclically substituted uracils and the use thereof
AU2018256591A1 (en)	2018-11-22	Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
TN2014000298A1 (en)	2015-12-21	Substituted annulated pyrimidines and triazines, and use thereof
CN104812762A8 (en)	2016-04-27	Substituted annulated pyrimidines and triazines, and use thereof
PH12015500274B1 (en)	2015-04-27	Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12015500983A1 (en)	2015-08-03	Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
TN2015000370A1 (en)	2017-01-03	Trifluormethyl-substituted ring-fused pyrimidines and use thereof
PH12014501738A1 (en)	2014-11-10	Piperidino-pyrimidine derivatives for the treatment of viral infections
TN2012000549A1 (en)	2014-04-01	Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
MY191389A (en)	2022-06-22	2-aminopyrimidine derivatives for the treatment of viral infections
PH12015500713A1 (en)	2015-05-18	Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
TN2016000107A1 (en)	2017-07-05	Substituted phenylalanine derivatives
PH12015500322A1 (en)	2015-03-30	Tris(hetero)arylpyrazoles and use thereof
TN2014000085A1 (en)	2015-07-01	Substituted annellated pyrimidine and the use thereof